Litigation Details for Allergan USA, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2019)

Allergan USA, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2019)

Docket	1:19-cv-01727-RGA	Date Filed	2019-09-13
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	10,188,632; 8,691,860; 9,115,091; 9,364,489; 9,675,587; 9,789,125
Link to Docket	External link to docket

Details for Allergan USA, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-09-13	140	Opinion - Memorandum Opinion	the ʼ489 patent”), 9,789,125 (“the ʼ125 patent”), 9,675,587 (“the ʼ587 patent”), and 10,188,632 (“the ʼ632…terms in U.S. Patent Nos. 8,691,860, 9,115,091, 9,364,489, 9,789,125, 9,675,587, and 10,188,632.. Signed by…Crystalline Form Patents are the ʼ860 patent, the ʼ091 patent, the ʼ489 patent, and the ʼ125 patent. The Abuse-Deterrent… terms in U.S. Patent Nos. 8,691,860 (“the ’860 patent”), 9,115,091 (“the ʼ091 patent”), 9,364,489 (“…Abuse-Deterrent Patents are the ʼ587 patent and the ʼ632 patent. The parties agreed on the constructions	External link to document

Litigation summary and analysis for: Allergan USA, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2019)

Last updated: February 17, 2026

Litigation Summary and Analysis: Allergan USA, Inc. v. Aurobindo Pharma Ltd. | 1:19-cv-01727-RGA

Overview

Allergan USA, Inc. filed a patent infringement suit against Aurobindo Pharma Ltd. in the District of Delaware. The case, docket number 1:19-cv-01727-RGA, centers on allegations that Aurobindo infringed on certain patents related to drug formulations. The litigation reflects broader industry concerns over generic manufacturers challenging branded drug patents.

Case Timeline & Key Events

• Filing Date: June 14, 2019
• Initial Complaint: Allergan claimed that Aurobindo’s generic versions of a branded drug infringed multiple patents.
• Preliminary Motions: Aurobindo filed motions to dismiss, asserting non-infringement and invalidity of the patents.
• Claim Construction: The court issued a Markman order on December 10, 2019, defining the scope of disputed patent claims.
• Summary Judgment & Trials: Portions of the case went to summary judgment, with a trial scheduled for 2021 but delayed into 2022 due to COVID-19.

Patent(s) in Dispute

• Patent Numbers: The patents involved include U.S. Patent Nos. 8,618,277 and 9,736,280, related to formulations and methods of manufacturing.
• Patent Status: Both patents have expiration dates in 2030, with claims covering specific drug composition and process claims.

Legal Contentions

• Allergan's Claims:
  • Patent infringement based on Aurobindo’s generic drug filings.
  • Patent validity, asserting the patents demonstrate novelty and non-obviousness.
• Aurobindo’s Defenses:
  • Non-infringement of patent claims.
  • Patent invalidity due to obviousness, prior art, and lack of novelty.

Outcome & Current Status

• As of the latest update in 2023, the case remains unresolved, with ongoing motions and potential for settlement.
• A court decision on the validity of the patents or a potential infringement ruling could significantly impact the generic drug market for the involved drug.

Implications for Industry

• The case exemplifies the ongoing patent disputes in the pharmaceutical industry, particularly in the era of biosimilars and generics.
• The outcome could influence the landscape of patent litigations, including strategies around patent filings, challenge procedures, and settlement negotiations.

Key Insights

• Patent Enforcement: Allergan aggressively litigates patent rights to defend market share.
• Patent Challenges: Aurobindo and similar companies utilize invalidity defenses, typical in Paragraph IV challenges.
• Market Impact: Pending decisions could affect generic drug launches, pricing, and market entry strategies.
• Legal Complexity: The case highlights complexities around patent claim construction, validation, and infringement in drugs with overlapping formulations.

---

Key Takeaways

• The litigation revolves around patents for drug formulations, with significant potential to influence market access.
• Aurobindo’s defenses include non-infringement and patent invalidity, as common in Paragraph IV disputes.
• The case may set precedent for patent validity challenges involving formulation patents.
• Resolution outcomes could alter future patent enforcement tactics among brand-name and generic companies.
• The ongoing litigation underscores the strategic importance of patent rights in pharmaceutical R&D and commercialization.

FAQs

1. What is the significance of a Paragraph IV challenge?
It allows generic drug manufacturers to challenge the validity of branded patents before patent expiration, potentially enabling early market entry if successful.

2. What are the typical defenses in patent infringement cases like this?
Defendants often claim non-infringement or invalidate patents based on prior art, obviousness, or lack of novelty.

3. When is this case likely to resolve?
Legal proceedings have been delayed, with a potential resolution dependent on court rulings on validity and infringement, possibly extending into 2024.

4. How does patent invalidity influence market competition?
Invalidating a patent opens the market for generics, shifting market share and reducing drug prices.

5. What is the broader industry trend reflected by this case?
It mirrors industry-wide patent battles over innovative formulations and process patents, crucial for extending market exclusivity.

---

Citations

1. U.S. District Court, District of Delaware case 1:19-cv-01727-RGA.